IBI363
Takeda and Innovent Forge $1.2B Upfront Oncology Pact for Bispecific and ADC Therapies, Total Deal Valued Up to $11.4B
Takeda; Innovent Biologics; global strategic partnership; bispecific antibody; antibody-drug conjugate (ADC); oncology; IBI363; IBI343; IBI3001; $1.2 billion upfront; $11.4 billion total deal; cancer therapy; co-development; milestone payments
Innovent Biologics Reports Promising Results in Early-Stage Study of Bispecific Antibody IBI363 in Lung Cancer Patients
Innovent Biologics, IBI363, Bispecific Antibody, Lung Cancer, Early-Stage Study, PD-1/IL-2 α-bias, Non-Small Cell Lung Cancer (NSCLC)